• Molecular Partners initiated a US multicenter Phase 1/2a trial of lead Radio-DARPin MP0712 in small cell lung cancer and other neuroendocrine cancers, with initial clinical data expected in 2026.
• First-patient imaging and dosimetry results from a compassionate-use program were already presented in January 2026, supporting plans to move forward with therapeutic dosing in the ongoing study.
• Separate investigator-led Phase 2 study of MP0317 in advanced cholangiocarcinoma has started in France, testing whether adding the tumor-localized CD40 agonist to standard treatment can improve patient outcomes versus standard treatment alone.
• Group ended Q1 2026 with CHF 79 million in cash and short-term time deposits, guiding to funding runway into late 2027 as it increases R&D spending to expand pipeline.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Molecular Partners AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605121600OMX_____CNEWS_EN_GNW9718729_en) on May 12, 2026, and is solely responsible for the information contained therein.